Patents by Inventor Gary F. Gerard
Gary F. Gerard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9862938Abstract: The present invention is in the fields of molecular and cellular biology. The invention is generally related to reverse transcriptase enzymes and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to reverse transcriptase enzymes which have been mutated or modified to increase thermostability, decrease terminal deoxynucleotidyl transferase activity, and/or increase fidelity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these reverse transcriptase enzymes or compositions. The invention also relates to nucleic acid molecules produced by these methods and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also concerns kits comprising such enzymes or compositions.Type: GrantFiled: May 7, 2014Date of Patent: January 9, 2018Assignee: Life Technologies CorporationInventors: Michael D. Smith, Robert Jason Potter, Gulshan Dhariwal, Gary F. Gerard, Kim Rosenthal, Jun E. Lee
-
Publication number: 20140363854Abstract: The present invention is in the fields of molecular and cellular biology. The invention is generally related to reverse transcriptase enzymes and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to reverse transcriptase enzymes which have been mutated or modified to increase thermostability, decrease terminal deoxynucleotidyl transferase activity, and/or increase fidelity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these reverse transcriptase enzymes or compositions. The invention also relates to nucleic acid molecules produced by these methods and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also concerns kits comprising such enzymes or compositions.Type: ApplicationFiled: May 7, 2014Publication date: December 11, 2014Inventors: Michael D. SMITH, Robert Jason Potter, Gulshan Dhariwal, Gary F. Gerard, Kim Rosenthal, Jun E. Lee
-
Publication number: 20120021464Abstract: The present invention is in the fields of molecular and cellular biology. The invention is generally related to reverse transcriptase enzymes and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to reverse transcriptase enzymes which have been mutated or modified to increase thermostability, decrease terminal deoxynucleotidyl transferase activity, and/or increase fidelity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these reverse transcriptase enzymes or compositions. The invention also relates to nucleic acid molecules produced by these methods and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also concerns kits comprising such enzymes or compositions.Type: ApplicationFiled: December 28, 2010Publication date: January 26, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Michael D. SMITH, Robert Jason POTTER, Gulshan DHARIWAL, Gary F. GERARD, Kim ROSENTHAL, Jun E. LEE
-
Patent number: 8043816Abstract: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention.Type: GrantFiled: May 18, 2009Date of Patent: October 25, 2011Assignee: Life Technologies CorporationInventors: Mekbib Astatke, Deb K. Chatterjee, Gary F. Gerard
-
Publication number: 20110160289Abstract: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention.Type: ApplicationFiled: May 3, 2010Publication date: June 30, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Mekbib ASTATKE, Deb K. Chatterjee, Gary F. Gerard
-
Publication number: 20110081704Abstract: The present invention is in the fields of molecular and cellular biology. The invention is generally related to reverse transcriptase enzymes and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to reverse transcriptase enzymes which have been mutated or modified to increase thermostability, decrease terminal deoxynucleotidyl transferase activity, and/or increase fidelity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these reverse transcriptase enzymes or compositions. The invention also relates to nucleic acid molecules produced by these methods and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also concerns kits comprising such enzymes or compositions.Type: ApplicationFiled: August 23, 2010Publication date: April 7, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Michael D. Smith, Robert Jason Potter, Gulshan Dhariwal, Gary F. Gerard, Kim Rosenthal
-
Publication number: 20110008770Abstract: The present invention is generally related to compositions and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to compositions comprising mixtures of polypeptides having reverse transcriptase (RT) activity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these compositions or polypeptides, particularly at temperatures above about 55° C. The invention also relates to nucleic acid molecules produced by these methods, to vectors and host cells comprising these nucleic acid molecules, and to the use of such nucleic acid molecules to produce desired polypeptides.Type: ApplicationFiled: July 29, 2009Publication date: January 13, 2011Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Gary F. Gerard, Michael D. Smith, Deb K. Chatterjee
-
Publication number: 20100190175Abstract: The invention is related generally to methods of amplifying or synthesizing or producing nucleic acid molecules using Translesion DNA polymerases. In particular, the invention relates to methods of introducing a random mutation into a nucleic acid and encoded polypeptide using Translesion DNA polymerases. The invention also relates to methods of introducing a modified nucleotide into a nucleic acid using Translesion DNA polymerases. The invention also relates to mutagenized and modified nucleic acid molecules and proteins produced by these methods, and to fragments or derivatives thereof. The invention also relates to vectors and host cells comprising mutagenized nucleic acid molecules, fragments, or derivatives. The invention also relates to the use of mutagenized nucleic acid molecules to produce desired polypeptides and uses of modified nucleic acid molecules to analyze samples. The invention also relates to kits or compositions or compounds for use in the invention or for carrying out the invention.Type: ApplicationFiled: March 18, 2010Publication date: July 29, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Gary F. Gerard, Zhihao Qiu, Martin Anthony Gleeson
-
Patent number: 7749708Abstract: The invention relates to methods for identifying the sequence of one or more variant nucleotides in a nucleic acid molecule. The method involves cleaving a double-stranded nucleic acid molecule containing a mismatch with a mismatch-specific endonuclease which cleaves on the 3? side of the mismatch, and preserving the integrity of the variant nucleotide by ligating a double-stranded linker with a 3?-overhang to said variant nucleotide. Because the variant nucleotide is immediately adjacent to the linker, PCR and/or sequence-by-synthesis analysis can be readily carried out.Type: GrantFiled: September 12, 2007Date of Patent: July 6, 2010Assignee: Transgenomic, Inc.Inventors: Paul D. Taylor, Gary F. Gerard, Reyes Candau
-
Publication number: 20100015683Abstract: The present invention is in the fields of molecular and cellular biology. The invention is generally related to reverse transcriptase enzymes and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to reverse transcriptase enzymes which have been mutated or modified to increase thermostability, decrease terminal deoxynucleotidyl transferase activity, and/or increase fidelity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these reverse transcriptase enzymes or compositions. The invention also relates to nucleic acid molecules produced by these methods and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also concerns kits comprising such enzymes or compositions.Type: ApplicationFiled: September 2, 2009Publication date: January 21, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Michael D. Smith, Robert Jason Potter, Gulsham Dhariwal, Gary F. Gerard, Kim Rosenthal
-
Publication number: 20090275100Abstract: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention.Type: ApplicationFiled: May 18, 2009Publication date: November 5, 2009Applicant: Life Technologies CorporationInventors: Mekbib Astatke, Deb K. Chatterjee, Gary F. Gerard
-
Patent number: 7579155Abstract: The invention relates to methods for identifying the sequence of one or more variant nucleotides in nucleic acid molecules. The method involves cleaving a double-stranded nucleic acid molecule containing a mismatch with a mismatch-specific endonuclease which cleaves on the 3? side of the mismatch, and preserving the integrity of the variant nucleotide by ligating a Double-Stranded Linker with a degenerate 3?-overhang to said variant nucleotide. Because the variant nucleotide is immediately adjacent to the linker, PCR and/or sequence-by-synthesis analysis can be readily carried out.Type: GrantFiled: April 11, 2008Date of Patent: August 25, 2009Assignee: Transgenomic, Inc.Inventors: Paul D. Taylor, Reyes Candau, Gary F. Gerard
-
Patent number: 7560261Abstract: The present invention relates to isolated nucleic acid sequences encoding CEL II endonuclease and vectors and host cells for producing a protein encoded thereby.Type: GrantFiled: May 18, 2005Date of Patent: July 14, 2009Assignee: Transgenomic, Inc.Inventors: Harini Shandilya, Gary F. Gerard, Peter Qiu
-
Publication number: 20090068652Abstract: The invention relates to methods for identifying the sequence of one or more variant nucleotides in a nucleic acid molecule. The method involves cleaving a double-stranded nucleic acid molecule containing a mismatch with a mismatch-specific endonuclease which cleaves on the 3? side of the mismatch, and preserving the integrity of the variant nucleotide by ligating a double-stranded linker with a 3?-overhang to said variant nucleotide. Because the variant nucleotide is immediately adjacent to the linker, PCR and/or sequence-by-synthesis analysis can be readily carried out.Type: ApplicationFiled: September 12, 2007Publication date: March 12, 2009Inventors: Paul D. Taylor, Gary F. Gerard, Reyes Candau
-
Publication number: 20090068659Abstract: The invention relates to methods for identifying the sequence of one or more variant nucleotides in nucleic acid molecules. The method involves cleaving a double-stranded nucleic acid molecule containing a mismatch with a mismatch-specific endonuclease which cleaves on the 3? side of the mismatch, and preserving the integrity of the variant nucleotide by ligating a Double-Stranded Linker with a degenerate 3?-overhang to said variant nucleotide. Because the variant nucleotide is immediately adjacent to the linker, PCR and/or sequence-by-synthesis analysis can be readily carried out.Type: ApplicationFiled: April 11, 2008Publication date: March 12, 2009Inventors: Paul D. Taylor, Reyes Candau, Gary F. Gerard
-
Publication number: 20080268520Abstract: The present invention relates generally to compositions and methods for enhancing recombinational cloning of nucleic acid molecules. In particular, the invention relates to compositions comprising one or more ribosomal proteins and one or more additional protein components required for recombinational cloning. More particularly, the invention relates to such compositions wherein the ribosomal proteins are one or more E. coli ribosomal proteins, still more particularly wherein the ribosomal proteins are selected from the group of E. coli ribosomal proteins consisting of S10, S14, S15, S16, S17, S18, S19, S20, S21, L20, L21, and L23 through L34, and most particularly S20, L27, and S15. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, in vitro and in vivo, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments.Type: ApplicationFiled: October 6, 2006Publication date: October 30, 2008Applicant: INVITROGEN CORPORATIONInventors: Gary F. Gerard, Elizabeth Flynn, A-Li W. Hu
-
Publication number: 20080171388Abstract: The present invention relates to nucleic acid inhibitors, compositions and method for enhancing synthesis of nucleic acid molecules. In a preferred aspect, the invention relates to inhibition or control of nucleic acid synthesis, sequencing or amplification. Specifically, the present invention discloses nucleic acids having affinity for polypeptides with polymerase activity for use in such synthesis, amplification or sequencing reactions. The nucleic acid inhibitors are capable of inhibiting nonspecific nucleic acid synthesis under certain conditions (e.g., at ambient temperatures). Thus, in a preferred aspect, the invention relates to “hot start” synthesis of nucleic acid molecules. Accordingly, the invention prevents, reduces or substantially reduces nonspecific nucleic acid synthesis. The invention also relates to kits for synthesizing, amplifying, reverse transcribing or sequencing nucleic acid molecules comprising one or more of the nucleic acid inhibitors or compositions of the invention.Type: ApplicationFiled: September 7, 2007Publication date: July 17, 2008Applicant: INVITROGEN CORPORATIONInventors: Mekbib Astatke, Deb K. Chatterjee, Gary F. Gerard
-
Publication number: 20080113354Abstract: Methods and kits are provided with DNA substrates having a fluorescent label positioned at a nucleotide internal from its 5? end for use with CEL nuclease to determine whether a DNA sequence contains mutations or polymorphic changes.Type: ApplicationFiled: November 14, 2005Publication date: May 15, 2008Inventors: Yanggu Shi, Gary F. Gerard
-
Patent number: 7129075Abstract: The present invention relates to the isolation and characterization of CEL I and CEL II endonuclease proteins. Methods and kits for identifying mismatches in double-stranded DNA are also provided.Type: GrantFiled: October 17, 2003Date of Patent: October 31, 2006Assignee: Transgenomic, Inc.Inventors: Gary F. Gerard, Harini Shandilya, Peter Qiu, James M. D'Alessio
-
Patent number: 7115406Abstract: A method of producing a Rous Sarcoma Virus reverse transcriptase (RSV RT) by expressing one orniore nucleic acid sequences encoding one or more subunits of RSV RT in a eukaryotic host cell and culturing the host cell under conditions sufficient to produce the recombinant RSV RT. The resulting RSV RT has a specific activity of between about 30,000 and 150,000 units per milligram and is suitable for methods including RT-polyinerase chain reaction (RT-PCR).Type: GrantFiled: November 13, 2002Date of Patent: October 3, 2006Assignee: Invitrogen CorporationInventors: Gary F Gerard, Michael D Smith, Deb K Chatterjee